Risk of lympho-haematological malignancies in patients with chronic plaque psoriasis: a systematic review with meta-analysis.
暂无分享,去创建一个
[1] D. Gladman,et al. Malignancy in psoriatic disease: Results from prospective longitudinal cohorts. , 2020, Seminars in arthritis and rheumatism.
[2] P. Gisondi,et al. Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks , 2020, Journal of clinical medicine.
[3] F. Carbonnel,et al. Systematic review with meta‐analysis: comparative risk of lymphoma with anti‐tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease , 2020, Alimentary pharmacology & therapeutics.
[4] J. Askling,et al. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype. , 2020, Rheumatology.
[5] J. Thyssen,et al. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease - A systematic review and meta-analysis. , 2020, Journal of Crohn's & colitis.
[6] L. Skov,et al. Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis. , 2020, JAMA dermatology.
[7] C. Massone,et al. Risk of mycosis fungoides in psoriatic patients: a critical review , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.
[8] Kyungdo Han,et al. Cancer risk in 892 089 patients with psoriasis in Korea: A nationwide population‐based cohort study , 2018, The Journal of dermatology.
[9] H. Prince,et al. Psoriasis and cancer. An Australian/New Zealand narrative , 2018, The Australasian journal of dermatology.
[10] L. Skov,et al. Psoriasis and risk of malignant lymphoma: a population‐based cohort study , 2018, The British journal of dermatology.
[11] M. Lebwohl,et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry , 2017, Journal of the American Academy of Dermatology.
[12] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[13] B. Nordstrom,et al. The risk of malignancy among biologic‐naïve pediatric psoriasis patients: A retrospective cohort study in a US claims database , 2017, Journal of the American Academy of Dermatology.
[14] X. Mariette,et al. Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas. , 2017, Journal of autoimmunity.
[15] J. Askling,et al. Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased? , 2017, Arthritis & rheumatology.
[16] Thomas G. Ray,et al. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population , 2017, Journal of the American Academy of Dermatology.
[17] M. Weinstock,et al. Personal history of psoriasis and risk of incident cancer among women: a population‐based cohort study , 2016, The British journal of dermatology.
[18] Daniel B. Shin,et al. The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network. , 2016, JAMA dermatology.
[19] R. Dummer,et al. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. , 2015, Journal of Crohn's & colitis.
[20] Ellen J. Kim,et al. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. , 2015, Dermatologic clinics.
[21] K. Hemminki,et al. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] K. Hemminki,et al. Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. , 2014 .
[23] R. Rosenquist,et al. Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces? , 2014, Seminars in cancer biology.
[24] M. Maître,et al. Risk of cancer in psoriasis: a systematic review and meta‐analysis of epidemiological studies , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[25] K. Reich,et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate‐to‐severe plaque psoriasis: results of a randomized, long‐term extension trial (RESTORE2) , 2013, The British journal of dermatology.
[26] E. Petridou,et al. Cigarette smoking and risk of lymphoma in adults: a comprehensive meta-analysis on Hodgkin and non-Hodgkin disease , 2013, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[27] M. Lai,et al. The risk of developing non‐melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10‐year, population‐based cohort study , 2012, International journal of dermatology.
[28] M. Suarez‐Almazor,et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. , 2012, JAMA.
[29] K. Papp,et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. , 2012, Journal of the American Academy of Dermatology.
[30] E. Sasso,et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. , 2012, Journal of the American Academy of Dermatology.
[31] Tzeng-Ji Chen,et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. , 2011, Journal of the American Academy of Dermatology.
[32] M. Lichtman. Obesity and the Risk for a Hematological Malignancy: Leukemia, Lymphoma, or Myeloma , 2010, The oncologist.
[33] P. Allavena,et al. Molecular pathways and targets in cancer-related inflammation , 2010, Annals of medicine.
[34] S. Piana,et al. Folliculotropic mycosis fungoides in a psoriatic patient under methotrexate treatment , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[35] S. Jick,et al. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. , 2009, The Journal of investigative dermatology.
[36] P. Fadda,et al. Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. , 2009, Cancer research.
[37] D. Moher,et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.
[38] K. Hemminki,et al. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden , 2009, British Journal of Cancer.
[39] J. Mitri,et al. Diabetes and Risk of Non-Hodgkin's Lymphoma , 2008, Diabetes Care.
[40] David Altshuler,et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus , 2008, Nature Genetics.
[41] F. Frasca,et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases , 2008, Archives of physiology and biochemistry.
[42] Daniel B. Shin,et al. The risk of lymphoma in patients with psoriasis. , 2006, The Journal of investigative dermatology.
[43] R. Stern. Lymphoma risk in psoriasis: results of the PUVA follow-up study. , 2006, Archives of dermatology.
[44] M. Kashani-Sabet,et al. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. , 2003, Journal of the American Academy of Dermatology.
[45] D. Margolis,et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. , 2003, Archives of dermatology.
[46] K. Gatter,et al. Lymphoproliferative disorders in Oxford renal transplant recipients , 2003, Journal of clinical pathology.
[47] L. Dubertret,et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. , 2003, The Journal of investigative dermatology.
[48] S. Weitzman,et al. Chronic inflammation and cancer. , 2002, Oncology.
[49] P. Boffetta,et al. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. , 2001, The Journal of investigative dermatology.
[50] D. Margolis,et al. The risk of malignancy associated with psoriasis. , 2001, Archives of dermatology.
[51] I. Olkin,et al. Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .
[52] A. Hannuksela-Svahn,et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. , 2000, The Journal of investigative dermatology.
[53] A. Hannuksela-Svahn,et al. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. , 1999, Journal of the American Academy of Dermatology.
[54] G. Frentz,et al. Malignant tumours and psoriasis: a follow‐up study , 1999, The British journal of dermatology.
[55] J. Karvonen,et al. Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. , 1996, Journal of the American Academy of Dermatology.
[56] D. Federman,et al. The epidemiology of non-Hodgkin's lymphoma. , 1996, Connecticut medicine.
[57] J. Olsen,et al. Malignant tumors in patients with psoriasis. , 1992, Journal of the American Academy of Dermatology.
[58] A. Kimball,et al. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. , 2015, Journal of the American Academy of Dermatology.
[59] P. Tugwell,et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .
[60] Miguel A Hernán,et al. The hazards of hazard ratios. , 2010, Epidemiology.
[61] Philippe Lafaille,et al. Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. , 2009, Archives of dermatology.